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Background: Succinate dehydrogenase (SDH) is a mitochondrial metabolic enzyme complex involved in both
the electron transport chain and the citric acid cycle. SDH mutations resulting in enzymatic dysfunction have
been found to be a predisposing factor in various hereditary cancers. Therefore, SDH has been implicated as a
tumor suppressor.
Results: We identified that dysregulation of SDH components also occurs in serous ovarian cancer, particularly
the SDH subunit SDHB. Targeted knockdown of Sdhb in mouse ovarian cancer cells resulted in enhanced
proliferation and an epithelial-to-mesenchymal transition (EMT). Bioinformatics analysis revealed that decreased
SDHB expression leads to a transcriptional upregulation of genes involved in metabolic networks affecting histone
methylation. We confirmed that Sdhb knockdown leads to a hypermethylated epigenome that is sufficient to promote
EMT. Metabolically, the loss of Sdhb resulted in reprogrammed carbon source utilization and mitochondrial dysfunction.
This altered metabolic state of Sdhb knockdown cells rendered them hypersensitive to energy stress.
Conclusions: These data illustrate how SDH dysfunction alters the epigenetic and metabolic landscape in ovarian
cancer. By analyzing the involvement of this enzyme in transcriptional and metabolic networks, we find a metabolic
Achilles’ heel that can be exploited therapeutically. Analyses of this type provide an understanding how specific
perturbations in cancer metabolism may lead to novel anticancer strategies.
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Ovarian cancer is the most lethal gynecological malig-
nancy in the United States, resulting in approximately
22,000 new diagnoses and 14,000 deaths in 2013 [1].
The prognosis of ovarian cancer is poor and has seen
limited improvement in the past few decades with a 5-year
survival rate of roughly 44% [2]. High-grade serous ovar-
ian cancer is the most common and most lethal subtype
of ovarian cancer, contributing to >70% of deaths from
ovarian cancer [3]. Integrative large-scale analyses of pa-
tient tumors with serous histology have revealed that the
disease is highly heterogeneous but can be clustered into* Correspondence: Paul-Joseph.Aspuria@cshs.org
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unless otherwise stated.several molecular subtypes with different clinical out-
comes [4,5]. One of the poor prognosis subtypes contains
an epithelial-mesenchymal transition (EMT) signature
[5]. Therefore, understanding and characterizing EMT in
ovarian cancer is of great importance.
EMT is a biological process that converts epithelial
cells to motile, mesenchymal cells [6]. It is largely defined
by the loss of plasma membrane E-cadherin and conversion
from a cobblestone-like morphology to a more spindle-
shaped and less adherent state. It was initially characterized
as a fundamental event in morphogenesis during embry-
onic tissue and organ development [7]. However, emerging
evidence suggests that cancer cells utilize the EMT pro-
gram to enhance invasiveness, increase migratory ability,
and acquire stem-like characteristics such as chemore-
sistance. EMT reprogramming involves several layers ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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especially in the context of cancer [6]. One area that has
not been extensively studied is the role of metabolic
enzymes in the regulation and maintenance of EMT.
Alterations in metabolism have been implicated in
cancer, with the main focus on the Warburg effect, a
phenomenon in which cancer cells upregulate glycolysis
and lactate production while decreasing glucose contribu-
tion to the citric acid (TCA) cycle in the mitochondria,
even in the presence of sufficient oxygen [8-10]. However,
mitochondrial metabolism is also important for cancer
proliferation. For example, mutations in the mitochondrial
enzyme succinate dehydrogenase (SDH) have been repor-
ted in a wide variety of cancers [11,12]. Also known as
mitochondrial respiratory Complex II, SDH is the only
enzyme to participate in both the TCA cycle and electron
transport chain (ETC.). In the TCA cycle, SDH catalyzes
the oxidation reaction where succinate is converted to
fumarate, which is coupled to the reduction of ubiquinone
to ubiquinol in the ETC. [12]. SDH is a holoenzyme con-
sisting of four essential subunits: SDHA (a flavoprotein),
SDHB (iron-sulfur protein), and two membrane anchor
units SDHC and SDHD. SDH assembly requires two fac-
tors, SDHAF1 and SDHAF2 [13], while its function is
influenced by the deacetylase activity of SIRT3 [14]. SDHx
loss-of-function mutations have been found to predispose
individuals to hereditary pheochromocytoma (PCC), para-
ganglioma (PGL), gastrointestinal stromal tumor (GIST),
and renal cell carcinoma [12]. Interestingly, it has been
shown that SDHx mutations are associated with hallmarks
of EMT in PCC and PGL as a result of alterations to the
epigenome [15,16]. Furthermore, the SDH regulators
SDHAF1 and SIRT3 have been identified as tumor sup-
pressor genes in lung and breast cancer, respectively
[14,17]. This has led to the definition of SDH as a mito-
chondrial tumor suppressor and a key player in cancer cell
differentiation.
Ovarian cancer is characterized by a remarkable degree
of genomic disarray but extremely low frequency of re-
current genomic alterations [4]. The dearth of common
therapeutic targets in ovarian cancer samples highlights
the need for individualized therapy or different approaches
to identifying patient groups with common character-
istics that can be therapeutically exploited. Interest-
ingly, succinate was identified as a potential metabolic
urinary biomarker for ovarian cancer [18], indicating that
altered SDH activity may be important in ovarian cancer
progression.
Here, we investigate whether alterations in SDH func-
tion also impact ovarian cancer biology. We find that dys-
regulation of SDH members occurs frequently in serous
ovarian cancer. Utilizing a mouse ovarian cancer cell line
as a model system, we find that knockdown of one of the
SDH subunits, Sdhb, increases aggressiveness and resultsin EMT. Sdhb knockdown cells were found to have a
hypermethylated epigenome whereby increased H3K27
methylation was sufficient to induce EMT. Using a meta-
bolomic approach to investigate the metabolic effects of
decreased SDH activity, we found that Sdhb knockdown
leads to altered glucose and glutamine utilization through
central carbon metabolism as well as mitochondrial
dysfunction. These data demonstrate the metabolic and
epigenetic consequences of decreased activity of a mito-
chondrial metabolic enzyme in ovarian cancer.
Methods
Plasmids and reagents
pLKO.1-based short hairpin constructs specific for mouse
Sdhb and human SDHB, as well as scrambled control
sequences, were obtained from Sigma-Aldrich (St. Louis,
MO, USA). shRNA sequences are listed in Additional
file 1: Table S1. GSK-J1 and GSK-J4 were obtained
from Tocris Bioscience (Bristol, Avon, UK). Metformin,
p-iodonitrotetrazolium, oligomycin, carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone chloride (FCCP),
and rotenone-myxothiazol were purchased from Sigma-
Aldrich.
Cell lines
C1 mouse ovarian cancer cells were generated as pre-
viously described [19-21]. HEY cells were obtained from
American Type Culture Collection (ATCC). Both cell
lines were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS unless otherwise
indicated.
Lentiviral-mediated gene knockdown
pLKO.1-sh1-Sdhb, pLKO.1-sh2-Sdhb, pLKO.1-sh1-SDHB,
pLKO.1-sh2-SDHB, and pLKO.1 scrambled shRNA plas-
mids were co-transfected with the delta 8.9 packaging
plasmid and VSVG plasmid into Lenti-X™ 293 T cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). After overnight incubation, the cell culture medium
was changed to DMEM supplemented with 30% FBS. The
medium was harvested 48 h later and filtered through a
0.45-μM filter. The viral supernatant was used for infec-
tion of C1 and HEY cells with polybrene (4 μg/ml).
Cells were infected overnight, and polyclonal populations
of stable transductants were selected with puromycin
(5 μg/ml) for 72 h.
Western blot analysis
Cell lysates were prepared using RIPA lysis buffer
(Sigma-Aldrich) containing a protease inhibitor cocktail
(Roche, Basel, Switzerland). Protein concentrations were
quantified by the BCA protein assay (Thermo Scientific,
Rockford, IL, USA). Fifty micrograms of lysate was loaded
onto a gradient gel (BioRad, Hercules, CA, USA) and
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fer to a PVDF nitrocellulose membrane (BioRad) was
performed using the Transblot Turbo transfer system
(BioRad). The membrane was then blocked in Odyssey
blocking buffer (LiCOR, Lincoln, NE, USA) for 30 min
and incubated with the appropriate antibody overnight at
4°C. Antibodies included E-cadherin (BD Biosciences, San
Jose, CA, USA), β-actin (Abcam, Cambridge, MA, USA),
Complex II Western Blot Antibody Cocktail that detects
SDHB (30 kDa) and Complex Va (60 kDa) (Abcam,
Burlungame, CA, USA), Methyl-Histone H3 Antibody
Sampler Kit (Cell Signaling, Danvers, MA, USA), and
SDHB (Santa Cruz Biotechnology, Dallas, TX, USA).
Membranes were then washed with TBS-T, incubated with
the appropriate secondary antibody for 1 h at room
temperature and then washed with TBS-T. The membrane
signal was subsequently analyzed by the LiCOR Odyssey
system (LiCOR Biosciences, Frankfurt, Germany).
qRT-PCR analysis
RNA was extracted using the RNeasy Miniprep Kit
(Qiagen, Valencia, CA, USA) and was reverse transcribed
to cDNA using the Quantitect Reverse Transcription Kit
(Qiagen). For qRT-PCR, 50 ng of cDNA was mixed with
the appropriate primers and the iQ SYBR-Green Super-
mix (BioRad) in a 96-well plate format. The qRT-PCR re-
action was performed using the CFX96 Real-Time System
(BioRad). Primer sequences are listed in Additional file 1:
Table S1.
Database mining
OncoPrints and the mRNA vs. CAN plot were generated
using the cBio Cancer Genomics Portal (http://www.
cbioportal.org) [22]. Tumorscape was analyzed as de-
scribed [23].
Immunofluorescence microscopy
Cells grown on coverslips were fixed with 3% paraformal-
dehyde for 20 min, washed with PBS, then permeabilized
with 0.1% Triton X-100/PBS for 10 min. This was fol-
lowed by incubation for 1 h at 37°C with E-cadherin anti-
body (1:1,000 dilution; BD Biosciences) or SDHB antibody
(1:100 dilution; Santa Cruz Biotechnology). After washing
with PBS, cells were incubated with appropriate fluo-
rescent secondary antibody (1:1,000 dilution; Invitrogen)
for 30 min at 37°C. The coverslips were mounted on slides
with Vectashield mounting medium with DAPI (Vector
Labs, Burlingame, CA, USA).
Succinate dehydrogenase assay
The SDH assay was performed using the Succinate
Dehydrogenase Activity Colorimetric Assay Kit (Biovision,
Milpitas, California, USA). Briefly, 1 × 107 cells were dounce
homogenized in 1 ml SDH assay buffer. Five microliters ofcell lysate were added to a mixture containing SDH assay
buffer, SDH substrate mix, and SDH probe. Absorbance
readings at 600 nm were taken every 3 min for a
total of 30 min. SDH activity was determined by the for-
mula B/(ΔT ×V) × Dilution factor, where B = amount of
reduced DCIP from standard curve (nmol), ΔT = reaction
time (min), V = sample volume added into the reaction
well (μl), and D = dilution factor.
Cell proliferation and drug treatment
Cells were seeded onto 6-well or 96-well plates at 5 × 104
or 1 × 103 cells/well, respectively. For the glucose and glu-
tamine withdrawal experiments, the medium was changed
to DMEM+ 10% FBS with indicated concentrations of
glucose or glutamine 24 h post-seeding. To assay cell pro-
liferation, triplicate cultures were trypsinized at the indi-
cated time points and counted using the trypan blue
exclusion method. To assay metformin sensitivity, various
concentrations of metformin were added to cultures in a
6-well plate 24 h post-seeding and cells were stained with
crystal violet at the indicated time points.
Soft agar growth
To assay anchorage-independent growth, 1 × 104 cells
were mixed with 0.5% agarose and overlayed on a 0.9%
agarose base layer in a 6-well plate. Plates were incubated
at 37°C for 3 weeks in a 5% CO2 incubator. Colonies were
stained with p-iodonitrotetrazolium chloride overnight
and counted using a stereomicroscope. Colony size was
measured using QCapture Pro™ (Q Imaging, Surrey, BC,
Canada).
Isotope labeling studies
For carbon tracing through central carbon metabolism,
cells were cultured for approximately 24 h in 10-cm
plates in glucose- and glutamine-free DMEM (Sigma
D5030, Sigma-Aldrich) containing 10% dialyzed FBS,
1% streptomycin/penicillin, naturally labeled 4 mM
glutamine or 25 mM glucose, and the appropriate tracer,
[U-13C6]glucose or [U-
13C5]glutamine (Cambridge Isotopes
Laboratories, Inc., Cambridge, MA, USA). After incuba-
tion, the medium was aspirated and each plate was rinsed
with 10 ml ice-cold saline. The saline was aspirated, and
cells were quenched with 2.89 ml of −20°C HPLC-grade
methanol. After adding 1.74 ml of ice water, the cells were
scraped with a cell lifter and collected in 15-ml conical
tubes. Chloroform (2.89 ml at −20°C) was added to each
tube and vortexed for 10 min at 4°C. Extracts were centri-
fuged at 4,000 × g for 15 min at 4°C. The upper aqueous
phase was collected in a separate tube and evaporated
under nitrogen for polar metabolite analysis. The metabo-
lites were analyzed using liquid chromatography tandem
mass spectrometry (LC-MS/MS) using a variation of the
method described previously [24]. A Paradigm MS4 HPLC
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Hydro column (4 μm particle size, 80 Å, 150 mm× 2 mm,
from Phenomenex, Torrance, CA, USA) were used for the
separation of metabolites by polarity. Prior to column sep-
aration, the samples were loaded onto a trapping column
(C18, 4 mm× 2 mm, from Phenomenex) and washed for
30 s with HPLC grade water containing 10 mM tributyla-
mine and 15 mM acetic acid for rapid desalting. HPLC
separation was coupled with negative-mode electrospray
ionization (ESI) to a TSQ Vantage triple stage quadrupole
mass spectrometer (Thermo Scientific, Waltham, MA,
USA) operating in multiple reactions monitoring (MRM)
mode. The LC parameters were as follows: autosampler
temperature, 10°C; injection volume, 10 μl; column tem-
perature, room temperature; and flow rate, 200 μl/minute.
The LC solvents were Solvent A: 10 mM tributylamine
and 15 mM acetic acid in 97:3 water:methanol (pH 4.95),
and Solvent B: methanol. Elution from the column was
performed over 50 minutes with the following gradient:
t = 0, 0% B; t = 5, 0% B; t = 10, 20% B; t = 20, 20% B; t = 35,
65% B; t = 38, 95% B; t = 42, 95% B, t = 43, 0% B; t = 50, 0%
B. ESI spray voltage was 3,000 V. Nitrogen was used as
sheath gas at 30 psi and as the auxiliary gas at 10 psi, and
argon as the collision gas at 1.5 mTorr, with the capillary
temperature at 325°C. Scan time for each MRM transition
was 0.1 second with a scan width of 1 m/z. The LC runs
were divided into time segments, with the MRM scans
within each time segment containing compounds eluting
during that time interval. For compounds eluting near
boundaries between time segments, the MRM scan corre-
sponding to the compound was conducted in both time
segments. Instrument control, chromatographic control,
and data acquisition were performed by the Xcalibar soft-
ware (Thermo Scientific). Data analysis was performed
using MAVEN [25,26]. The protein content of extracted
cells was determined from the dried protein fraction from
each extraction, which was incubated overnight in 2 ml of
0.2 M KOH and quantified by Bradford assay. Isotope
labeling data was corrected for the natural abundance of
different isotopes using IsoCor [27].
Glucose consumption and lactate excretion rates
Glucose and lactate levels in the media were analyzed at
time 0 and after 72 h using LC-MS/MS. An H-Class
UPLC system and AQCUITY UPLC BEH Amide column
(2.1 × 100 mm, 1.7 μm particle size, from Waters) were
used for the separation of glucose and lactate. UPLC sep-
aration was coupled with negative-mode ESI to a Waters
Xevo TQ-S mass spectrometer operating in MRM mode.
The LC parameters were as follows: autosampler tempe-
rature, 5°C; injection volume, 5 μl; column temperature,
50°C; and flow rate, 400 μl/min. The LC solvents were
solvent A, 50 mM ammonium formate in water (pH 3)
and solvent B, acetonitrile. Elution from the column wasperformed over 2 min with an isocratic gradient of 40%
solvent A and 60% solvent B. The capillary voltage was
2.92 kV, and the cone voltage was 50 V. The flow rates of
cone gas and desolvation gas were 150 and 600 L/h,
respectively. The source temperature was 150°C, and the
desolvation temperature was 500°C. Argon was used as
collision gas at 1.5 mTorr. Collision energies and source
cone potentials were optimized for each transition using
Waters QuanOptimize software. Data were acquired using
MassLynx 4.1 and QuanLynx software. The following
equation was used to calculate metabolite consumption/
excretion per 106 cells per hour, denoted as α:
α ¼ metabolite½ initial‐ metabolite½ finalX initial
μ ⋅ e
μΔt−1ð Þ
where
μ ¼ specific growth rate ¼ 1
t
⋅ln
X final
X initial
 
and X is the cell number and t is the time in hours.
Cellular oxygen consumption and extracellular
acidification rates
Cellular metabolic rates were measured using an XF24
Analyzer (Seahorse Bioscience, North Billerica, MA, USA)
as previously described [28]. Mixing, waiting, and meas-
urement times were 4, 2, and 2 min and 2, 3, and 3 min
for C1 and HEY cells, respectively. The measurements
were normalized against protein concentration. The con-
centrations for compounds injected during the analysis
were 100 μM 2,4 dinitrophenol, 0.5 μM oligomycin, 1 μM
FCCP, 1 μM rotenone-myxothiazol and 0.75 μM oligomy-
cin, 0.5 μM FCCP, 0.75 μM rotenone-myxothiazol for C1
cells and HEY cells, respectively. Data was obtained using
the XF24 Analyzer software.
RNA-seq
Extracted RNA was enriched using the Ribominus™
Eukaryote Kit (Invitrogen). The Ion PI™ Template OT2
200 Kit (Invitrogen) was used to prepare the RNA library
for sequencing. Sequencing was performed using the Ion
Proton™ Sequencer (Life Technologies, Grand Island, NY,
USA). Fragments per kilobase of exon per million
reads (FPKM) were calculated using TopHAT and
Cufflinks [29].
Gene set analysis
Genes with FPKM smaller than 5 were discarded, leaving
a total of 6,503 genes for further analysis. The log2 fold
change (i.e., log2 of the FPKM ratio) was used as the
gene-level statistic. The gene set analysis was carried out
using the R/Bioconductor package piano [30]. Three
types of gene set collections were used, describing the
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and metabolic pathways, and (iii) Gene Ontology (GO)
terms.
The human genome-scale metabolic network HMR2
was used to define the metabolite gene sets [31]. HMR2
contains gene associations for its enzymatic reactions, so
for each metabolite, all genes that are associated with
reactions in which the metabolite takes part are grouped
into a gene set. The metabolic pathway gene sets were
defined by all genes associated to reactions belonging to
an individual pathway. Each set of human genes was
translated into a set of mouse genes by mapping the
human Ensembl gene identifiers to mouse Ensembl gene
identifiers using the R/Bioconductor package biomaRt
[32]. This package was also used to acquire the GO term
gene. Gene set analysis was carried out separately for
the metabolites, pathways, and GO terms. In all cases,
the gene set statistics were calculated using piano with the
median method and the gene set p values were calculated
using gene permutation (10,000 permutations). The piano
package calculates scores for several directionality classes.
We primarily relied on the distinct-directional class for
the identification of gene sets that are coordinately regu-
lated in a distinct direction (up or down). Supplemental
materials and methods are found in Additional file 2.
Results
SDH pathway members are downregulated in serous
ovarian cancer
The Cancer Genome Atlas (TCGA) provides an exhaust-
ive catalog of molecular changes for specific cancer types
[4]. An analysis of the TCGA ovarian cancer dataset
revealed significant genomic deletions of SDH members
in 67% of serous ovarian cancer patient samples, with
heterozygous deletion of SDHB found in 39% of the
samples (Figure 1A). Heterozygous loss of SDHB corre-
lated with decreased SDHB mRNA levels relative to dip-
loid samples (Figure 1B). Statistically significant focal
deletion of SDHB (q < .01) was confirmed in Tumors-
cape, a dataset that includes whole genome analyses of
somatic copy number alterations (CNA) in 110 ovarian
cancer samples [23] (Figure 1C). Recurrent hemizygous
deletions have been found to enrich for genes involved
in growth inhibition thereby optimizing proliferative po-
tential [33,34]. It has been proposed that the majority of
tumor suppressor genes are likely to be haploinsufficient
and selected for during the evolution of a cancer [34].
Homozygous focal deletions are rare in ovarian cancer
[4], suggesting that haploinsufficiency may be the preferred
mechanism for tumor progression. Immunohistochemical
staining of ovarian carcinoma tissue microarray was used to
determine levels of SDHB protein in malignant tumor cells
relative to adjacent nonmalignant stroma. SDHB protein was
detected in cytoplasmic granules in most cells, which isconsistent with its predicted localization at the mitochondrial
membrane. Of 211 ovarian cancer samples that had sufficient
stromal and epithelial components for evaluation, seven sam-
ples exhibited significantly decreased levels of SDHB in
tumor epithelia relative to tumor stroma (Additional file 3:
Figure S1). Together, these data suggest that decreased SDH
activity through altered expression of SDHBmay be biologic-
ally relevant in a subset of ovarian cancers.
Knockdown of Sdhb results in EMT in mouse ovarian
cancer cells
Given our analyses of the TCGA and Tumorscape data-
sets, we focused on the most frequently downregulated
SDH subunit, Sdhb. We utilized C1 mouse ovarian can-
cer cells that are p53 deficient and express C-myc and
K-rasG12D. These genetically defined cells have been pre-
viously used as a system to elucidate the function of
putative oncogenes in ovarian cancer [19-21]. Two shRNA
constructs targeting Sdhb were used to generate stable
Sdhb knockdown cell lines. Western blotting showed that
both constructs (sh1-Sdhb and sh2-Sdhb) decreased the
amount of SDHB expression relative to the scrambled
control (Figure 2A). This was further confirmed by
immunofluorescence (Additional file 4: Figure S2). Sdhb
knockdown cell lines (C1-sh1-Sdhb and C1-sh2-Sdhb)
showed a significant decrease in SDH activity relative to
the control (Figure 2B). Knockdown of Sdhb resulted in
an increased proliferation rate and an enhanced ability to
form colonies in soft agar relative to the control C1-scr
cells (Figure 2C,D). This effect on soft agar growth was
also seen upon SDHB knockdown in the human ovarian
cancer cell line, HEY (Additional file 5: Figure S3A,B). In
addition to their augmented growth capability, Sdhb
knockdown cells were more elongated and spindle-shaped
compared to the cobblestone morphology of the control
cells (Figure 2E). This morphological change resembled
EMT. To determine the involvement of EMT at the mo-
lecular level, we analyzed Sdhb knockdown and control
cells for membrane localization of E-cadherin, which is
frequently lost during EMT. Immunofluorescence analysis
revealed E-cadherin staining at the plasma membrane in
C1-scr cells (Figure 2E). In contrast, E-cadherin localized
within cytoplasmic punctate structures in Sdhb knock-
down cells (Figure 2E). Quantitative RT-PCR analysis of
mRNA levels of various transcription factors involved in
EMT (Snai1, Snai2, Twist1, and Twist2) revealed their
upregulation in Sdhb knockdown cells relative to the
control cells, with the most dramatic increase in Twist2
(Figure 2F). Decreased expression of E-cadherin and
increased expression of TWIST1/2 in Sdhb knockdown
cells were also seen on the protein level (Figure 2A).
Typically under induction of EMT, cells continue to pro-
liferate at the same level or arrest to promote invasion and
migration [35]. However, the increased proliferation in C1
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Overall Focal
SDHA 8.74 0.97 1
SDHB 30.1 19.42 0.00669
SDHC 6.8 2.91 1
SDHD 28.16 4.85 1
Figure 1 SDH components are downregulated in serous ovarian cancer. (A) Oncoprint depicting 575 patient samples with genetic loss of
SDH subunits. Light blue and dark blue indicate heterozygous deletion and homozygous deletion, respectively. (B) A plot showing the relationship
between SDHB mRNA abundance and copy number alteration of the SDHB gene. (C) Tumorscape copy number data for SDH subunits tabulated. Bold
face indicates significance (q value < .01).
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explained by the overriding proliferative signal in these
cells due to c-myc overexpression. Indeed, several studies
have shown that various EMT-inducing factors, especially
TWIST1/2, synergize with other oncogenic aberrations
to enhance proliferation [36-38]. These data suggest that
Sdhb knockdown transforms mouse ovarian cancer cells
to a more aggressive and mesenchymal state.
Knockdown of Sdhb leads to histone hypermethylation
To identify how the loss of Sdhb led to EMT, we investi-
gated the transcriptional regulation of cellular metabol-
ism upon Sdhb knockdown. C1-scr and C1-sh1-Sdhb
cells were first subjected to RNA-seq. The extracted data
was then integrated with a recently published compre-
hensive human genome-scale metabolic network, HMR2
[39]. HMR2 represents a holistic view of metabolism byproviding associations between metabolites, reactions,
and their corresponding enzyme-coding genes, which we
mapped to mouse homologs to match the RNA-seq gene
annotation. For each metabolite, we constructed a gene
set consisting of all enzymes catalyzing reactions in which
the metabolite takes part, i.e., genes that control the flux
through that metabolite. Next, we performed gene set
analysis on the metabolite gene sets using the log2 fold
changes of the genes to score each metabolite [30]. Gene
sets (metabolites) found significant in this analysis are
termed reporter metabolites [40] and represent hotspots
in the metabolic network around which significant tran-
scriptional regulation occurs (Figure 3A, Additional file 6:
Table S2). Interestingly, S-adenosyl methionine (SAM),
S-adenosyl homocysteine (SAH), and tetrahydrofolate
(THF), relevant metabolites in the SAM cycle, were all
identified as reporter metabolites (p < 0.005) influenced
Figure 2 Sdhb knockdown in mouse ovarian cancer cells leads to EMT. (A) Western blot detection of SDHB, E-cadherin, and TWIST2 after
shRNA-mediated knockdown of Sdhb. β-actin was used as a loading control. (B) SDH assay illustrating the decrease in SDH activity upon knockdown of
Sdhb. (C) Cell proliferation with counts taken at indicated time points. C1-scr is in black, while C1-sh1-Sdhb and C1-sh2-Sdhb are in red. Ratios are relative
to C1-scr at the specified time point. (D) Formation of colonies in soft agar. (E) Bright field cell morphology and immunofluorescent visualization of
E-cadherin. (F) Quantification of Snai1, Snai2, Twist1, and Twist2 mRNA by qRT-PCR. Gapdh was used as a control. Statistical significance is based upon
student t-test. Experiments were performed in triplicate and repeated at least three times. *p value < .01.
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cycle, the reactive methyl group in SAM is transferred
to a substrate in a transmethylation reaction producing
SAH. If the substrate is a histone methyltransferase
(HMT), this can subsequently methylate the histones,
thus influencing the epigenome.
To further validate the transcriptional influence on
histone methylation, we performed an additional gene set
analysis using GO terms as gene sets. In Figure 3C,
GO terms significantly enriched with upregulated genes
(p < 0.05) and relevant to histone methylation are shown,
clearly indicating a pattern of increased histone methy-
lation regulated on the transcriptional level (complete
results are presented in Additional file 6: Table S2). In
summary, Sdhb knockdown appears to be orchestrating a
transcriptional program in which histone methylation is
promoted or maintained, possibly through upregulation of
the SAM cycle.
To confirm whether histone methylation was affected,
we analyzed by Western blot various methylated histone
marks in Sdhb knockdown and control cells. Indeed,
Sdhb knockdown cells had elevated levels of histone H3dimethylated K4, K9, K27, and K36 marks in comparison
to control cells (Figure 4A). We further investigated the
aberration in H3K27 methylation because of its known
association with malignant progression [41]. There are
two known H3K27 demethylases, JMJD3 and UTX, in
mammalian cells. Highly selective H3K27 demethylase
inhibitors, GSK-J1 and GSK-J4 (a more cell permeable
derivative of GSK-J1), have been developed [42]. To
determine whether chemical inhibition of H3K27 his-
tone demethylases could lead to EMT, C1-scr cells were
treated with DMSO or each inhibitor for 5 days. DMSO-
treated cells exhibited cobblestone morphology, while
treatment with GSK-J1 or GSK-J4 resulted in a spindle-
shaped and elongated cell morphology analogous to Sdhb
knockdown (Figure 4B). To confirm that EMT occur-
red in cells treated with H3K27 demethylase inhibitors,
E-cadherin localization was analyzed by immunofluores-
cence. Indeed, E-cadherin was localized to punctate cyto-
plasmic structures in cells treated with GSK-J1 or GSK-J4
as opposed to the plasma membrane staining found in the
DMSO-treated control cells (Figure 4C). Cells treated with
GSK-J1 and GSK-J4 also had elevated levels of Snai2 and
A B 
C 
Figure 3 Histone methylation is transcriptionally promoted after Sdhb knockdown. (A) For topological analysis of metabolism, a human
genome-scale metabolic network was used where the gene reaction association was mapped from human to mouse genes. Reporter metabolites,
hotspots in metabolism around which significant transcriptional changes occur, are highlighted in red (upregulation) and blue (downregulation)
nodes in the network when comparing C1-scr against C1-sh1-Sdhb cells. (B) A subnetwork found to be transcriptionally affected was S-Adenosyl
methionine (SAM) metabolism. Both SAM, S-adenosyl homocysteine (SAH) and tetrahydrofolate (THF) were identified as reporter metabolites significantly
(p < 0.005) affected by transcriptional upregulation of their neighboring enzymes. (C) A selection of GO terms related to histone methylation found
significantly (p < 0.05) enriched by upregulated genes. The bar plot shows the number of upregulated and downregulated genes in each GO term
and their individual fold changes in red and blue.
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http://www.cancerandmetabolism.com/content/2/1/21Twist2 mRNA relative to the DMSO-treated control cells
as determined by qRT-PCR (Figure 4D). These data show
that hypermethylation of H3K27 is sufficient to induce
EMT, suggesting that the hypermethylated epigenome
induced by the loss of Sdhb may be responsible for the
EMT phenotype.
Sdhb knockdown leads to reprogrammed glucose and
glutamine utilization
Given the fact that SDH is intricately involved in central
carbon metabolism through its role in the TCA cycle
and ETC, we examined global metabolite levels in the
C1-scr and C1-sh1-Sdhb cells by LC-MS/MS. As expec-
ted, Sdhb knockdown cells had elevated levels of succin-
ate and decreased levels of fumarate and malate relative
to C1-scr cells (Figure 5A). This metabolic signature
confirms the decrease in SDH activity upon Sdhb knock-
down. In addition to altering TCA cycle intermediates
succinate, fumarate, and malate, Sdhb knockdown af-
fected many intracellular metabolites including aminoacids, nucleotides, and intermediates in glycolysis as
well as the pentose phosphate pathway (Additional file 7:
Figure S4). Interestingly, Sdhb knockdown led to a sig-
nificant increase of methylmalonic acid, possibly due to
the feedback inhibition of succinate-CoA ligase (SUCL) by
succinate (Additional file 7: Figure S4).
To further probe metabolic alterations caused by Sdhb
knockdown, we used isotope-labeled nutrients combined
with mass spectrometry-based techniques to trace glu-
cose and glutamine through central carbon metabolism.
Analysis of intracellular metabolites after culturing cells
in the presence of uniformly labeled 13C-glucose ([U-13C6]
glucose) revealed that Sdhb knockdown increased glucose
contribution to sedoheptulose-7-phosphate and adenosine
triphosphate (ATP); in contrast, glucose contribution to
TCA cycle intermediate succinate was decreased (Figure 5B).
Consistently, succinate and glutamate labeling from uni-
formly labeled 13C-glutamine ([U-13C5]glutamine) was
increased (Figure 5C). This increased glutamine utiliza-
tion by Sdhb knockdown cells is highlighted by their
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Figure 4 Sdhb knockdown leads to a hypermethylated epigenome; small-molecule inhibition of H3K27 demethylases phenocopies loss
of Sdhb. (A) Western blot of various histone methylation marks with Histone H3 as a loading control. (B) Bright field microscopy of untreated
cells or cells treated with indicated concentrations of GSK-J1 or GSK-J4 for 4 days. (C) Immunofluorescent microscopy of cells stained for E-cadherin
(green) and DAPI (blue). (D) Quantification of Snai1, Snai2, and Twist2 mRNA relative to Gapdh. *p value < .01.
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http://www.cancerandmetabolism.com/content/2/1/21increased uptake of glutamine relative to the control
cells (Figure 5D). These data suggest that Sdhb knockdown
increases glucose contribution to the pentose phosphate
pathway and nucleotide biosynthesis to support rapid
proliferation. Increased nucleotide synthesis from glucose
is achieved by decreasing glucose contribution to the TCA
cycle, which is compensated by increasing glutamine
contribution to the TCA cycle. Intracellular pool levels
also support a model in which nucleotide biosynthesis is
upregulated, as many glycolytic and pentose phosphate
pathway intermediates are increased in response to Sdhb
knockdown (Additional file 7: Figure S4).
Given the increased use of glutamine in Sdhb knock-
down cells, we hypothesized that these cells have an aug-
mented dependency on glutamine for survival relative to
the control cells. To test this, we assayed the effect of
varying glutamine concentration on cell proliferation.
Indeed, in lower glutamine concentrations, C1-sh1-Sdhb
cells grew slower in comparison to the control C1-scr cells
(Figure 5E). Therefore, knockdown of Sdhb leads to a
greater reliance on glutamine for cell survival.Sdhb knockdown results in a mitochondrial reserve
capacity defect that can be exploited by metformin
Since Sdhb knockdown alters central carbon metabolism
including the TCA cycle occurring in the mitochondria,
we investigated the effect of Sdhb knockdown on mito-
chondrial activity. A key indicator of mitochondrial func-
tion is the oxygen consumption rate (OCR). To ascertain
specific mitochondrial perturbations, the OCR of C1-scr
and C1-sh1-Sdhb cells was determined during sequential
treatment with compounds that modulate mitochondrial
activity. Oligomycin, a F1F0 ATP synthase inhibitor, blocks
proton movement, thereby inhibiting oxidative phosphor-
ylation (OXPHOS). FCCP reestablishes proton movement
by dissipating the mitochondrial membrane potential to
stimulate maximal O2 consumption and electron trans-
port [43]. Finally, rotenone/myxothiazol, complex I and III
inhibitors, completely block mitochondrial respiration.
Both cell lines had similar basal OCR and responses to
oligomycin and rotenone (Figure 6A). However, the cell
lines responded differently to FCCP treatment (Figure 6A).
The calculated difference between FCCP-induced and
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Figure 5 Carbon source utilization is altered upon Sdhb knockdown. (A) Mass spectrometry analysis of intracellular succinate, fumarate, and
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http://www.cancerandmetabolism.com/content/2/1/21basal OCR indicates reserve respiratory capacity. FCCP
injection increased respiration 59% in C1-scr while spare
respiratory capacity was nonexistent in C1-sh1-Sdhb cells
(Figure 6A). Thus, C1-sh1-Sdhb cells respirate at their
maximum capacity. SDHB knockdown in HEY cells resul-
ted in a lower basal respiration implying a greater reliance
on SDH respiration in this particular cell line (Additional
file 5: Figure S3C). Therefore, knockdown of Sdhb de-
creases mitochondrial reserve respiratory capacity.
The reserve respiratory capacity must be sufficient to
provide enough ATP during times of energy stress. If
ATP demands are not met, affected cells risk being
driven into senescence or cell death [44]. To determine
whether the decreased reserve capacity of Sdhb knock-
down cells rendered them sensitive to energy stress, C1-scr
and C1-sh1-Sdhb cells were cultured in normal media then
switched to media with varying amounts of glucose.
Despite the previous observation that Sdhb knockdowncells grew at a faster rate than control cells under nor-
mal growth conditions (Figure 2B), C1-sh1-Sdhb cells
grew at a slower rate than C1-scr cells upon glucose
withdrawal (Figure 6B). In fact, the majority of Sdhb knock-
down cells appeared to undergo apoptosis (Figure 6C).
Consistent with the increased dependence of C1-sh1-Sdhb
cells on glucose relative to C1-scr cells, C1-sh1-Sdhb cells
were more glycolytic (Figure 6D), took up glucose and
excreted lactate at increased levels relative to C1-scr
cells (Figure 6E). We suspect that the effect of glucose
starvation on the Sdhb knockdown cells is twofold, a
failure to adapt to the decrease in glycolytic ATP and
its reliance on the pentose phosphate pathway for nucleo-
tide biosynthesis.
Since C1-sh1-Sdhb cells are hypersensitive to glucose
starvation, we were interested if this bioenergetics defi-
ciency could be therapeutically exploited. Metformin, a
commonly used antidiabetic drug, inhibits Complex I in
Figure 6 The bioenergetics defect of Sdhb knockdown cells can be exploited with metformin. (A) The oxygen consumption rate (OCR)
was analyzed by the Seahorse XF24 Bioanalyzer in basal conditions and in response to sequential treatment with oligomycin (ATP synthase
inhibitor), FCCP (dissipates mitochondrial membrane potential), and rotenone-myxothiazol (complex I inhibitor). (B, C) Cells grown in normal
media were switched to media with or without glucose after 24 h. (B) After 48 h, cells were counted by trypan blue exclusion or (C) visualized
by light microscopy. (D) The extracellular acidification rate (ECAR), an indicator of glycolysis, was analyzed by the Seahorse XF24 Bioanalyzer in
basal conditions. (E) Mass spectrometry analysis of lactate and glucose in spent media of C1-scr and C1-sh1-Sdhb cells. Media was collected at 0 and
72 h. The y-axis depicts fold change of lactate secretion and glucose depletion relative to C1-scr cells. (F) Cells were treated with various concentrations
of metformin for 3 days. Cells were visualized by crystal violet staining and extracted dye was quantified by a fluorescent plate reader.
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http://www.cancerandmetabolism.com/content/2/1/21the ETC [45]. This reduces the cellular energy charge,
a measure of the energetic state of the cell’s adenine
nucleotide pool defined as ([ATP] + 0.5[ADP]) / ([ATP] +
[ADP] + [AMP]) [46]. To determine if metformin-induced
energy stress had a differential effect on C1-scr and
C1-sh1-Sdhb cells, cells were exposed to various con-
centrations of metformin. C1-sh1-Sdhb cells were hyper-
sensitive to metformin treatment relative to C1-scr cells
(Figure 6F). Specifically, metformin inhibited growth of
the control and Sdhb knockdown cells with IC50 values of
29.73 and 14.73 mM, respectively (Figure 6F). Taken to-
gether, these results implicate a crucial role for Sdhb in
the response to bioenergetic insult.
Discussion
Various mechanisms have been proposed for SDH-
associated malignancy. Due to SDH’s role in the ETC, it
has been suggested that reactive oxygen species (ROS)can be induced by SDH-inactivating mutations, which
contributes to genomic instability, DNA damage, and
other tumorigenic phenomena [47]. However, Sdhb
knockdown did not lead to altered ROS levels, and
the antioxidant N-acetylcysteine (NAC) had no effect
on various Sdhb knockdown phenotypes in our system
(Additional file 8: Figure S5A). Interestingly, many studies
have focused on the idea that succinate itself can act
as an oncometabolite. Due to its structural similarity to
α-ketoglutarate (α-KG), succinate has been found to
competitively inhibit α-KG-dependent dioxygenases.
This phenomenon was first described linking succinate to
HIF1α stabilization; succinate was found to directly inhibit
prolyl hydroxylases which serve to degrade HIF1α [48,49].
However, we did not find altered HIF signaling between
the control and Sdhb knockdown cells (Additional file 8:
Figure S5B). This may be due in part to the modestly
elevated levels of succinate in our Sdhb knockdown cells,
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http://www.cancerandmetabolism.com/content/2/1/21approximately six-fold vs. control (Figure 5A), in compari-
son to previous studies (approximately 100-fold in tumors
and approximately 300-fold upon complete knockout of
Sdhb in mouse cells) [16,50]. It is also possible that HIF
signaling by SDHx mutations is tissue-dependent, thus
explaining the specific range of cancers induced by
SDH inactivation. Recently, the repertoire of α-KG-
dependent dioxygenases targeted by succinate has ex-
panded to include epigenome-modifying enzymes such
as the TET family of 5-methylcytosine hydroxylases
and histone demethylases [51]. Inhibition of these enzymes
by elevated levels of succinate leads to genome-wide his-
tone and DNA methylation [51,52]. In support of this
idea, SDHx-related PGL tumors were found to display a
hypermethylator phenotype, where epigenetic silencing
was particularly severe in SDHB-mutated tumors [16].
This association between SDHx mutations and hyperme-
thylation was also found in GIST [53]. Our data further
support this model in which SDH inhibition leads to a
hypermethylated epigenome. It has been suggested that
a stronger hypermethylator phenotype, which associates
with stronger downregulation of target genes, may con-
tribute to the metastatic phenotype [16]. Our results are
in line with this idea as aberrant hypermethylation of
H3K27 in mouse ovarian cancer cells was sufficient for
EMT, thereby implicating the link between epigenetic
remodeling and cell state [16]. However, overexpression
of the H3K27 demethylases, UTX and JMJD3, in Sdhb
knockdown cells failed to reverse EMT, thereby indicating
a higher complexity to the maintenance of the mesenchy-
mal state (Additional file 9: Figure S6). This is likely due to
transcriptional upregulation of metabolic and epigenetic
networks to support this hypermethylated state. Therefore,
SDH dysfunction is a contributor of the tumorigenic pro-
cess via mitochondrion-to-nuclear signaling.
In addition to SDH activity being linked to epigenetic
reprogramming, we also found that Sdhb knockdown
leads to reprogrammed glucose and glutamine utilization.
Specifically, increased glucose flux into the pentose phos-
phate pathway and increased glutamine usage in the TCA
cycle. Interestingly, these phenomena mimic disruption of
another TCA cycle enzyme, fumarate hydratase (FH), in
mouse kidney cells [54]. The mechanism by which SDH
dysfunction leads to these effects is unknown. One possi-
bility is that the global epigenetic changes induced by
Sdhb knockdown may lead to an altered transcriptome as
evidenced by pathway enrichment analysis of the RNA-
seq data (Additional file 7: Figure S4). The analysis indi-
cated that the pentose phosphate pathway and nucleotide
metabolism gene sets were both upregulated. The gene
set analysis also showed that genes associated with oxi-
dative phosphorylation were significantly downregulated
(Additional file 10: Figure S7). In similar fashion, the MYC
proto-oncogene has been shown to directly control thetranscription of various genes involved in several meta-
bolic pathways including glycolysis, the pentose phosphate
pathway, and glutaminolysis [55,56]. Also, the glycolytic
enzyme fructose-1,6-biphosphatase (FBP1) has been shown
to influence metabolic reprogramming to impact EMT
progression [57]. How SDH dysfunction affects the regula-
tion of these enzymes will be an interesting subject of
future research. Interestingly, an association between
glutamine dependence and cancer invasiveness has been
recently found in ovarian cancer, thereby providing fur-
ther support for carbon source reprogramming to support
different ovarian cancer states [58].
Conclusions
Although SDH dysfunction leads to enhanced cancer
aggressiveness, it also results in metabolic vulnerabilities
due to its involvement in both the TCA cycle and ETC.
We showed that altered carbon source utilization in
Sdhb knockdown cells renders them hypersensitive to
both glucose and glutamine starvation. Also, by analyz-
ing mitochondrial function, we found that SDH dysfunc-
tion leads to a decreased mitochondrial reserve capacity
that can be exploited by energy stress caused by either
glucose withdrawal or metformin treatment. Interestingly,
it has been shown that combinatorial treatment with met-
formin and the glycolytic inhibitor 2-deoxyglucose are
effective in a broad spectrum of pre-clinical cancer models
[59]. Therefore, it is worth exploring the possibility that
tumors with SDHx mutations can be therapeutically tar-
geted by exploiting their metabolic state.
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Additional file 1: Table S1. shRNA and qRT-PCR sequences.
Additional file 2: Supplementary materials and methods.
Additional file 3: Figure S1. SDHB protein expression in high-grade
ovarian carcinoma. Representative images of tumors with (A) ubiquitous
SDHB expression in epithelial and stromal cells and (B) decreased SDHB
expression in epithelial cells relative to stromal cells. T, tumor; S, stroma.
Additional file 4: Figure S2. Immunofluorescence staining of SDHB in
C1-scr and Sdhb knockdown cells.
Additional file 5: Figure S3. SDHB knockdown in HEY cells results in
enhanced anchorage-independent growth and a defect in mitochondrial
function. (A) Western blot detection of SDHB after shRNA-mediated
knockdown. Complex V alpha was used as a loading control. (B) Colony
size in soft agar. (C) OCR was analyzed by the Seahorse XF24 Bioanalyzer
in basal conditions and in response to sequential treatment with oligomycin,
FCCP, and rotenone-myxothiazol. *p value < .01.
Additional file 6: Table S2. Table of reporter metabolites and GO terms.
Additional file 7: Figure S4. Global analysis of metabolites in C1-scr
and C1-sh1-Sdhb cells. Steady state levels of metabolites in control and
Sdhb knockdown cells were determined by mass spectrometry. A heat
map was generated using Cluster 3.0 for unsupervised clustering and
JavaTreeView for visualization.
Additional file 8: Figure S5. Sdhb knockdown does not affect ROS
levels or HIF signaling in C1 cells. (A) C1-scr and C1-sh1-Sdhb cells were
incubated with MitoTracker® Red CM-H2XRos to determine relative ROS
Aspuria et al. Cancer & Metabolism 2014, 2:21 Page 13 of 15
http://www.cancerandmetabolism.com/content/2/1/21levels. No significant difference in probe intensity was observed. (B)
HIF-response element luciferase activity in Sdhb knockdown and control
cells. Data are normalized to renilla luciferase activity and shown relative
to C1-scr cells.
Additional file 9: Figure S6. Overexpression of H3K27 demethylases,
JMJD3 and UTX, does not promote MET in Sdhb knockdown cells.
C1-sh1-Sdhb and C1-sh2-Sdhb cells were transfected with HA-tagged JMJD3,
UTX, or GFP constructs. Lysates were collected 7 days post-transfection.
Western blot detection of HA-tagged JMJD3 and UTX, E-cadherin, and
β-actin.
Additional file 10: Figure S7. Sdhb knockdown affects the
transcriptional regulation of the metabolism of amino acids, nucleotides,
and oxidative phosphorylation. In order to identify metabolic pathways
influenced by transcriptional regulation, we performed a gene set
analysis using the pathways defined by the human genome-scale
metabolic network HMR2. The resulting heat map shows the top significant
pathways affected by transcriptional changes. The leftmost and rightmost
columns show p values for the pathways being coordinately regulated in a
distinct direction. The second columns from the left and right show the
p values for pathways having a significant subset of upregulated or
downregulated genes. The middle column shows the p values for pathways
affected by transcriptional regulation in general, regardless of the direction.
The pentose phosphate pathway, providing backbones for both nucleotides
and amino acids, is upregulated. This pattern is also seen for pathways
related to nucleotide metabolism and amino acid metabolism (marked in
red). Oxidative phosphorylation is significantly downregulated (marked
in blue). For the relevant pathways, p values <0.04 are marked with a
black box.
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